1. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003
2. DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007 Apr 26;356(17):1723-35.
3. Lundgren J, Reiss P, Worm S, Weber R, El-Sadr W, De Wit S, Law M, D’Arminio MonforteA, Pradier C, Sabin C, and Aquataine, AHOD, ATHENA, INSIGHT, EuroSIDA, ICONA, Nice, SHCS, St Pierre Cohorts & D:A:D Study Group. Risk of Myocardial Infarction with Exposure to Specific ARV from the PI, NNRTI, and NRTI Drug Classes: The D:A:D Study. Abstract 44LB, 16th CROI 2009.
4. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccata F, Costagliela D, and the Clinical Epi Group of the French Hosp Database on HIV. Disponibile a Impact of Specific NRTI and PI Exposure on the Risk of Myocardial Infarction: A Case-Control Study Nested within FHDH ANRS CO4. Abstract 43LB, 16th CROI 2009.
5. Murphy R, Zala C, Berzins B, Fichtenbaum C, Dube M, Guaraldi G, Torriani F, Belsey E, Mitchell C, Stein J, and SABAR Study Team.Disponibile a Endothelial Function, Lipoproteins, and Cardiovascular Inflammatory Markers in Treated HIV-infected Patients with Hyperlipidemia Who Were Switched to an Atazanavir-containing Regimen or Continued on Other Protease Inhibitor-based Therapy: Switch to Atazanavir and Brachial Artery Reactivity Study. Abstract 722, 16th CROI 2009.